Chromenopyrazole-based High Affinity, Selective Fluorescent Ligands for Cannabinoid Type 2 Receptor

被引:31
|
作者
Singh, Sameek [1 ]
Oyagawa, Caitlin R. M. [2 ,3 ]
Macdonald, Christa [2 ,3 ]
Grimsey, Natasha L. [2 ,3 ]
Glass, Michelle [2 ,3 ,4 ]
Vernall, Andrea J. [1 ]
机构
[1] Univ Otago, Sch Pharm, Dunedin, New Zealand
[2] Univ Auckland, Sch Med Sci, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland, New Zealand
[3] Univ Auckland, Sch Med Sci, Ctr Brain Res, Fac Med & Hlth Sci, Auckland, New Zealand
[4] Univ Otago, Dept Pharmacol & Toxicol, Dunedin 9016, New Zealand
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2019年 / 10卷 / 02期
关键词
GPCR; cannabinoid type 2 receptor; fluorescent ligand; chemical tool; CB2; RECEPTOR; ENDOCANNABINOID SYSTEM; SCAFFOLD; AGONISTS; PROBES; TOOLS;
D O I
10.1021/acsmedchemlett.8b00597
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Cannabinoid type 2 receptor (CB2R) is an attractive target for the treatment of pain and inflammatory disorders. Availability of a selective CB2R fluorescent ligand to study CB2R expression and localization in healthy and disease conditions would greatly contribute to improving our understanding of this receptor. Herein, we report a series of chromenopyrazole-based CB2R fluorescent ligands. The highest affinity fluorescent ligand was Cy5-containing 24 (hCB(2)R pK(i), = 7.38 +/- 0.05), which had 131-fold selectivity over CB1R. In a cAMP BRET assay, 24 behaved as a potent CB2R. inverse agonist. Widefield imaging experiments showed that 24 binds to CB2R in live cells with good selectivity and low levels of nonspecific fluorescence. The high affinity, selectivity, and suitable imaging properties of fluorescent ligand 24 make it a valuable tool for studying CB2R.
引用
收藏
页码:209 / 214
页数:11
相关论文
共 50 条
  • [21] New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists
    Faundez-Parraguez, Manuel
    Alarcon-Miranda, Carlos
    Cho, Young Hwa
    Pessoa-Mahana, Hernan
    Gallardo-Garrido, Carlos
    Chung, Hery
    Faundez, Mario
    Pessoa-Mahana, David
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (20)
  • [22] Design, Synthesis, Binding and Docking-Based 3D-QSAR Studies of 2-Pyridylbenzimidazoles-A New Family of High Affinity CB1 Cannabinoid Ligands
    Mella-Raipan, Jaime A.
    Lagos, Carlos F.
    Recabarren-Gajardo, Gonzalo
    Espinosa-Bustos, Christian
    Romero-Parra, Javier
    Pessoa-Mahana, Hernan
    Iturriaga-Vasquez, Patricio
    David Pessoa-Mahana, Carlos
    MOLECULES, 2013, 18 (04) : 3972 - 4001
  • [23] Radiosynthesis and evaluation of new PET ligands for peripheral cannabinoid receptor type 1 imaging
    Yamasaki, Tomoteru
    Fujinaga, Masayuki
    Shimoda, Yoko
    Mori, Wakana
    Zhang, Yiding
    Wakizaka, Hidekatsu
    Ogawa, Masanao
    Zhang, Ming-Rong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (17) : 4114 - 4117
  • [24] Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor
    Moldovan, Rares-Petru
    Teodoro, Rodrigo
    Gao, Yongjun
    Deuther-Conrad, Winnie
    Kranz, Mathias
    Wang, Yuchuan
    Kuwabara, Hiroto
    Nakano, Masayoshi
    Valentine, Heather
    Fischer, Steffen
    Pomper, Martin G.
    Wong, Dean F.
    Dannals, Robert F.
    Brust, Peter
    Horti, Andrew G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (17) : 7840 - 7855
  • [25] Synthesis and biological evaluation of ferrocene-based cannabinoid receptor 2 ligands
    Sansook, Supojjanee
    Tuo, Wei
    Bollier, Melanie
    Barczyk, Amelie
    Dezitter, Xavier
    Klupsch, Frederique
    Leleu-Chavain, Natascha
    Farce, Amaury
    Tizzard, Graham J.
    Coles, Simon J.
    Spencer, John
    Millet, Regis
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (06) : 631 - 638
  • [26] Cannabinoid receptor ligands as potential anticancer agents - high hopes for new therapies?
    Oesch, Susanne
    Gertsch, Juerg
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 (07) : 839 - 853
  • [27] N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)
    Graziano, Giovanni
    Delre, Pietro
    Carofiglio, Francesca
    Brea, Jose
    Ligresti, Alessia
    Kostrzewa, Magdalena
    Riganti, Chiara
    Gioe-Gallo, Claudia
    Majellaro, Maria
    Nicolotti, Orazio
    Colabufo, Nicola Antonio
    Abate, Carmen
    Loza, Maria Isabel
    Sotelo, Eddy
    Mangiatordi, Giuseppe Felice
    Contino, Marialessandra
    Stefanachi, Angela
    Leonetti, Francesco
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 248
  • [28] Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists
    Fulo, Harvey F.
    Shoeib, Amal
    Cabanlong, Christian, V
    Williams, Alexander H.
    Zhan, Chang-Guo
    Prather, Paul L.
    Dudley, Gregory B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (09) : 6381 - 6396
  • [29] Targeting the cannabinoid CB2 receptor:: Mutations, modeling and development of CB2 selective ligands
    Raitio, KH
    Salo, OMH
    Nevalainen, T
    Poso, A
    Järvinen, T
    CURRENT MEDICINAL CHEMISTRY, 2005, 12 (10) : 1217 - 1237
  • [30] Mechanistic QSAR analysis to predict the binding affinity of diverse heterocycles as selective cannabinoid 2 receptor inhibitor
    Jawarkar, Rahul D.
    Zaki, Magdi E. A.
    Al-Hussain, Sami A.
    Alzahrani, Abdullah Yahya Abdullah
    Ming, Long Chiau
    Samad, Abdul
    Rashid, Summya
    Mali, Suraj
    Elossaily, Gehan M.
    JOURNAL OF TAIBAH UNIVERSITY FOR SCIENCE, 2023, 17 (01):